Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Metabolic subgroups and cardiometabolic multimorbidity in the UK Biobank

View ORCID ProfileAnwar Mulugeta, View ORCID ProfileElina Hyppönen, View ORCID ProfileMika Ala-Korpela, View ORCID ProfileVille-Petteri Mäkinen
doi: https://doi.org/10.1101/2021.02.01.21250893
Anwar Mulugeta
1Australian Centre for Precision Health, Unit of Clinical and Health Sciences, University of South Australia, Adelaide, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anwar Mulugeta
Elina Hyppönen
1Australian Centre for Precision Health, Unit of Clinical and Health Sciences, University of South Australia, Adelaide, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Elina Hyppönen
Mika Ala-Korpela
2Computational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland
3Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Oulu, Finland
4NMR Metabolomics Laboratory, School of Pharmacy, University of Eastern Finland, Kuopio, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mika Ala-Korpela
Ville-Petteri Mäkinen
1Australian Centre for Precision Health, Unit of Clinical and Health Sciences, University of South Australia, Adelaide, Australia
5Computational and Systems Biology Program, Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ville-Petteri Mäkinen
  • For correspondence: ville-petteri.makinen@sahmri.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Ischemic heart disease (IHD), diabetes, cancer and dementia share features of age-associated metabolic dysfunction. We hypothesized that metabolic diversity explains the diversity of morbidity later in life.

Methods We analyzed data from the UK Biobank (N = 329,908). A self-organizing map (SOM, an artificial neural network) was trained with 51 metabolic traits adjusted for age and sex. The SOM analyses produced six subgroups that summarized the multi-variable metabolic diversity. The subgroup with the lowest adiposity and disease burden was chosen as the reference. Hazard ratios (HR) were modeled by Cox regression (P < 0.0001 unless otherwise indicated). Enrichment of multi-morbidity over random expectation was tested by permutation analysis.

Results The subgroup with the highest sex hormones was not associated with IHD (HR = 1.04, P = 0.14). The subgroup with high urinary excretion without kidney stress (HR = 1.24) and the subgroup with the highest apolipoprotein B and blood pressure (HR = 1.52) were associated with IHD. The subgroup with high adiposity, inflammation and kidney stress was associated with IHD (HR = 2.11), cancer (HR= 1.29), dementia (HR = 1.70) and mortality (HR = 2.12). The subgroup with high triglycerides and liver enzymes was at risk of diabetes (HR = 15.6). Paradoxical enrichment of multimorbidity in young individuals and in favorable subgroups was observed.

Conclusions These results support metabolic diversity as an explanation to diverging morbidity and demonstrate the potential value of population-based metabolic subgroups as public health targets for reducing aggregate burden of chronic diseases in ageing populations.

Key messages

  • We introduced six data-driven subgroups of the UK Biobank as a high-dimensional model of metabolic diversity and disease risk within a human population.

  • Three subgroups captured features of the classical cardiometabolic spectrum with stratification along cholesterol and blood pressure, kidney or liver dysfunction and systemic inflammation.

  • Two novel subgroups of high sex hormones and high urinary excretion were observed.

  • We defined a new concept of multimorbidity enrichment.

  • nexpected patterns of multimorbidity indicated that metabolically “healthy” individuals with one cardiometabolic disease may be at a disproportional synergistic risk of co-morbidity.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

This study is based on data from UK Biobank cohort.

Funding Statement

This work was supported by the NHMRC grant GNT1157281. MAK was supported by a research grant from the Sigrid Juselius Foundation, Finland.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

UK Biobank obtained informed consent from each participant, and ethical approval was granted by the National Information Governance Board for Health and Social Care and North West Multi-centre Research Ethics Committee (11/NW/0382). The current study is approved by the UK Biobank under application number 29890.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data will be made available through application to the UK Biobank.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted February 03, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Metabolic subgroups and cardiometabolic multimorbidity in the UK Biobank
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Metabolic subgroups and cardiometabolic multimorbidity in the UK Biobank
Anwar Mulugeta, Elina Hyppönen, Mika Ala-Korpela, Ville-Petteri Mäkinen
medRxiv 2021.02.01.21250893; doi: https://doi.org/10.1101/2021.02.01.21250893
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Metabolic subgroups and cardiometabolic multimorbidity in the UK Biobank
Anwar Mulugeta, Elina Hyppönen, Mika Ala-Korpela, Ville-Petteri Mäkinen
medRxiv 2021.02.01.21250893; doi: https://doi.org/10.1101/2021.02.01.21250893

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (161)
  • Allergy and Immunology (416)
  • Anesthesia (91)
  • Cardiovascular Medicine (860)
  • Dentistry and Oral Medicine (159)
  • Dermatology (97)
  • Emergency Medicine (250)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (394)
  • Epidemiology (8562)
  • Forensic Medicine (4)
  • Gastroenterology (384)
  • Genetic and Genomic Medicine (1753)
  • Geriatric Medicine (167)
  • Health Economics (373)
  • Health Informatics (1244)
  • Health Policy (621)
  • Health Systems and Quality Improvement (468)
  • Hematology (196)
  • HIV/AIDS (374)
  • Infectious Diseases (except HIV/AIDS) (10303)
  • Intensive Care and Critical Care Medicine (553)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (212)
  • Neurology (1678)
  • Nursing (97)
  • Nutrition (251)
  • Obstetrics and Gynecology (326)
  • Occupational and Environmental Health (451)
  • Oncology (929)
  • Ophthalmology (263)
  • Orthopedics (102)
  • Otolaryngology (172)
  • Pain Medicine (114)
  • Palliative Medicine (40)
  • Pathology (253)
  • Pediatrics (536)
  • Pharmacology and Therapeutics (253)
  • Primary Care Research (208)
  • Psychiatry and Clinical Psychology (1770)
  • Public and Global Health (3841)
  • Radiology and Imaging (624)
  • Rehabilitation Medicine and Physical Therapy (320)
  • Respiratory Medicine (520)
  • Rheumatology (208)
  • Sexual and Reproductive Health (168)
  • Sports Medicine (158)
  • Surgery (190)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)